Actively Recruiting
UZ/KU Leuven Program for Post-mortem Tissue Donation to Enhance Research
Led by Universitaire Ziekenhuizen KU Leuven · Updated on 2024-06-28
100
Participants Needed
1
Research Sites
769 weeks
Total Duration
On this page
Sponsors
U
Universitaire Ziekenhuizen KU Leuven
Lead Sponsor
K
KU Leuven
Collaborating Sponsor
AI-Summary
What this Trial Is About
UPTIDER is a prospective, interventional, non-Investigational Medicinal Product (non-IMP), non-commercial, single centre post-mortem tissue donation program for metastatic breast cancer patients or patients with a germline pathogenic variant with a moderate to high lifetime risk of breast cancer and at least one malignancy at time of death. The overarching objective of UPTIDER is (i) to unravel metastatic breast cancer evolution, biology, heterogeneity and treatment resistance and (ii) to assess pathogenicity and tumour biology in hereditary cancer syndromes with a high lifetime risk of breast cancer; both through extensive post-mortem multi-level and multi-region sample analysis.
CONDITIONS
Official Title
UZ/KU Leuven Program for Post-mortem Tissue Donation to Enhance Research
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 6 18 years
- Signed informed consent
- Diagnosis of metastatic breast cancer or hereditary cancer syndrome with moderate to high lifetime breast cancer risk, treated or followed at UZ Leuven or referred there for the trial
- For the pilot phase: no additional criteria
- For the ILC substudy: histologically confirmed invasive lobular carcinoma
- For the IBC substudy: history of inflammatory breast cancer with rapid onset symptoms and pathological confirmation
- For hereditary cancer syndrome substudy: confirmed germline mutation linked to moderate/high breast cancer risk and at least one malignant lesion at inclusion
- For other substudies: no additional criteria
You will not qualify if you...
- Presence of transmissible diseases that risk health of researchers or handlers, including HIV, active hepatitis C, unknown encephalitis, Creutzfeldt-Jakob disease, rabies, active malaria, active tuberculosis, or active SARS-CoV-2 infection
- Factors impeding study logistics or sampling within reasonable post-mortem time, including living far from UZ Leuven or outside Belgium, or inability to notify clinicians/researchers promptly after death
- For ILC and IBC substudies: diagnosis of another malignancy within 5 years before inclusion, except basal cell or squamous cell skin carcinoma and in situ cervical carcinoma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UZ Leuven
Leuven, Belgium, 3000
Actively Recruiting
Research Team
G
Giuseppe Floris, MD PhD
CONTACT
C
Christine Desmedt, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here